How to Store Exenatide: Stability and Handling, Per the Research

Exenatide is a prescription medicine, a synthetic version of exendin-4 that acts as a glucagon-like peptide-1 (GLP-1) receptor agonist. Its development history traces to a peptide isolated from Gila monster venom, which was characterised and then developed into an approved anti-diabetic agent (PMID 21194543). Because exenatide is a 39 amino acid peptide supplied as a sterile aqueous product, its handling follows the storage conventions used across injectable peptide medicines: cold chain before first use, defined limits once in use, and protection from light, freezing and mechanical stress.

This page summarises what stability literature and approved product labeling report about exenatide storage and handling. It does not describe preparation, dosing or administration. This page is for educational purposes only and is not medical advice; consult a licensed physician or the dispensing pharmacist for any question about a specific product, its labeling, or its use.

Why Exenatide Is Handled as a Cold-Chain Peptide

Exenatide belongs to the incretin mimetic class described in reviews of GLP-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes (PMID 17098089). Reviews of glucose homeostasis regulation by GLP-1 explain that native GLP-1 is degraded within minutes by dipeptidyl peptidase-4, and that exendin-4 based agents resist that cleavage, giving a far longer biological half-life in circulation (PMID 24373234). That resistance is enzymatic, in vivo. It is a separate question from physical and chemical stability in a vial or pen sitting on a shelf, which is governed by temperature, pH, light, agitation and container surface chemistry.

General peptide stability science, rather than exenatide-specific trials, supplies the mechanisms that matter for storage. Aqueous peptide solutions are susceptible to hydrolysis, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, aggregation and fibrillation, and adsorption of peptide onto glass and plastic surfaces. Each of those pathways has a temperature dependence, which is the core reason peptide products are refrigerated rather than stored warm. Where a claim below is exenatide-specific, it is labelled as such; where it reflects general peptide chemistry, that is stated too.

Refrigeration: What Labeling and Formulation Work Report

Approved exenatide products are distributed under cold chain and their labeling directs refrigeration between 2 and 8 degrees Celsius (36 to 46 degrees Fahrenheit) before first use, with protection from light and an explicit instruction not to freeze. Both the twice-daily immediate-release presentation and the extended-release microsphere presentation carry refrigerated storage conditions in their approved labeling. The authoritative version of those conditions for any given product is the leaflet packaged with it, which a pharmacist can confirm.

Formulation research gives some insight into why refrigeration is specified for the extended-release form in particular. A 2022 study mapped the in vivo microclimate pH distribution inside exenatide-encapsulated poly(lactic-co-glycolic acid) microspheres and reported that acidic microenvironments develop within the polymer matrix as it hydrolyses, a condition relevant to peptide stability inside the depot (PMID 36030989). Researchers in that work used microclimate pH mapping to characterise the environment the encapsulated peptide experiences. Polymer hydrolysis is temperature-accelerated, which is consistent with microsphere products being held cold until shortly before use.

What the refrigerated range is meant to prevent

• Chemical degradation, including deamidation and hydrolysis, which proceed faster at higher temperatures in general peptide chemistry.
• Aggregation, in which monomeric peptide associates into dimers, oligomers and eventually insoluble particles; this is a well-recognised failure mode for aqueous peptide formulations.
• Preservative and excipient drift in multi-dose presentations, where buffer and antimicrobial components also have temperature-dependent shelf lives.

Shelf Life and the In-Use Period

Two separate clocks apply to exenatide products, and they are routinely confused. The first is the expiry date printed on the carton, which applies to an unopened product kept continuously within its labelled refrigerated range. The second is the in-use period, a shorter window that begins at first use and runs regardless of whether the product is returned to the refrigerator afterwards. For immediate-release exenatide pens, labeling specifies an in-use period measured in weeks after first use, during which the pen may be kept refrigerated or at controlled room temperature below 25 degrees Celsius. The exact number of days and the exact temperature ceiling differ between products and between national labels, so the packaged leaflet is the governing document.

A broader point from formulation literature is that the in-use clock exists because the moment a container is pierced or a pen is first actuated, the product's environment changes: headspace air, microbial ingress risk and repeated temperature cycling all begin. None of those are captured by the unopened expiry date.

Room Temperature and Travel

Labeling for immediate-release exenatide permits storage below a stated room temperature ceiling during the in-use period, which is what makes routine travel with the product feasible under a clinician's or pharmacist's direction. Excursions above that ceiling are a different matter. Peptide degradation kinetics are generally temperature-dependent in an approximately exponential way, so brief exposure to a hot vehicle interior or direct sun is not equivalent to a longer exposure at mild room temperature.

Research into alternative exenatide delivery systems illustrates how much formulation context shapes thermal tolerance. A 2016 study described a long-acting phospholipid gel of exenatide developed for long-term therapy of type II diabetes, reporting sustained release from the gel depot (PMID 26857900). A 2018 study developed a chitosan-based thermosensitive hydrogel for nasal delivery of exenatide and reported that magnesium chloride influenced the gel system's behaviour (PMID 30389472). A 2022 study described two-layer sustained-release microneedles encapsulating exenatide for type 2 diabetes treatment (PMID 35745827). These are investigational delivery platforms studied in preclinical models, not approved presentations, and their storage characteristics do not transfer to the marketed products. They are cited here only to show that the carrier, not just the peptide, determines storage behaviour.

The same logic applies to oral delivery research. A study of heteropolymer ferritin nanocages as delivery vehicles for oral delivery of GLP-1 peptides reported on nanocage-based carriers designed to protect peptide cargo through the gastrointestinal tract (PMID 41005135). Protection strategies of that kind exist precisely because unprotected peptides are fragile in hostile chemical environments, which is the same vulnerability that drives cold-chain handling of the injectable products.

Freezing and Freeze-Thaw

Approved exenatide labeling directs that the product not be frozen, and that a product which has been frozen should not be used. This is one of the more absolute statements in peptide product labeling, and the reason comes from general protein and peptide formulation science rather than exenatide-specific trials. Freezing concentrates solutes in the shrinking unfrozen fraction, shifts local pH as buffer components crystallise at different rates, and creates large ice-water interfaces at which peptides can unfold and aggregate. Those changes are not reliably reversed on thawing, and the resulting aggregates may not be visible.

For extended-release microsphere presentations, freezing introduces an additional concern: mechanical stress on the polymer matrix. The microclimate inside such microspheres was characterised in the 2022 PLGA mapping study, which reported pH heterogeneity within the particles in vivo (PMID 36030989). Any disruption of matrix integrity has the potential to change release behaviour, which is why labeling for depot formulations treats freezing as disqualifying rather than merely undesirable.

Signs of Degradation Described in the Literature

Labeling for clear aqueous exenatide solutions directs visual inspection before use, with discoloration or visible particulate matter described as reasons the product should not be used. For suspension presentations, the expected appearance after mixing is described in the leaflet, and deviations from it are similarly treated as disqualifying. The general stability indicators that formulation scientists monitor include:

• Visible particulates or flocculation in a solution expected to be clear, consistent with aggregation.
• Cloudiness or haze developing in a previously clear solution.
• Discoloration, often associated with oxidation pathways.
• Loss of potency without visible change, which is the reason analytical assays rather than eyesight define shelf life. A product can be chemically degraded and still look normal.

That last point is the important one. Visual inspection is a screen for gross failure, not a stability test. The expiry date and in-use period exist because potency loss is frequently invisible.

Where Exenatide Sits Among GLP-1 Agents

Exenatide was among the first incretin mimetics brought to clinical application, a transition described in reviews covering the move from therapeutic concept to clinical use (PMID 17383951). Later agents in the class were developed with different molecular scaffolds; a review of albiglutide, for instance, discussed an albumin-fused GLP-1 agent as an option in diabetes mellitus (PMID 26796275). Each product in the class carries its own storage conditions tied to its own formulation, so storage information for one GLP-1 receptor agonist does not transfer to another.

Exenatide has also been studied outside glycaemic control. A 2019 study reported that exenatide ameliorated inflammatory responses in human rheumatoid arthritis fibroblast-like synoviocytes (PMID 30897288), and a 2017 review discussed GLP-1 based therapy in the context of bariatric surgery for metabolic disease (PMID 28276830). Those are research contexts; they do not change the storage conditions of the approved products.

Related Reading

• How to store peptides: general stability principles
• Exenatide: an evidence overview

Questions about whether a specific exenatide product was stored correctly, whether an excursion matters, or what a given leaflet requires are answered by the prescribing clinician or dispensing pharmacist with the product in hand.

References

• Mapping in vivo microclimate pH distribution in exenatide-encapsulated PLGA microspheres (Journal of Controlled Release, 2022)
• Regulation of glucose homeostasis by GLP-1 (Progress in Molecular Biology and Translational Science, 2014)
• Exenatide ameliorates inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes (IUBMB Life, 2019)
• Two-Layer Sustained-Release Microneedles Encapsulating Exenatide for Type 2 Diabetes Treatment (Pharmaceutics, 2022)
• Bariatric surgery - time to replace with GLP-1? (Scandinavian Journal of Gastroenterology, 2017)
• Heteropolymer ferritin nanocages as delivery vehicles for oral delivery of GLP-1 peptides (Journal of Colloid and Interface Science, 2026)
• Albiglutide: Is a better hope against diabetes mellitus? (Biomedicine & Pharmacotherapy, 2016)
• Chitosan-based thermosensitive hydrogel for nasal delivery of exenatide: Effect of magnesium chloride (International Journal of Pharmaceutics, 2018)
• Long-Acting Phospholipid Gel of Exenatide for Long-Term Therapy of Type II Diabetes (Pharmaceutical Research, 2016)
• The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent (Toxicon, 2012)
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes (Lancet, 2006)
• Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application (Orvosi Hetilap, 2007)